Novel therapies for hepatitis C - one pill fits all?
作者： Michael P. Manns , Thomas von Hahn
DOI: 10.1038/NRD4050
关键词:
摘要: Almost 25 years after the hepatitis C virus (HCV) was identified, and following intense research development efforts, a large number of direct-acting antiviral drugs are now beginning to reach patient care. Accordingly, way in which care is delivered evolving at breath-taking pace. Here, we review current upcoming treatment options for HCV, describe key challenges facing clinicians drug developers discuss how landscape HCV arena will change over coming years.
nature.com
sci-hub.se 参考文章(115)
K J Blight, E V Agapov, K E Reed, C M Rice, A A Kolykhalov, Molecular virology of hepatitis C virus: an update with respect to potential antiviral targets. Antiviral Therapy. ,vol. 3, pp. 71- 81 ,(1998)
Shimian Zou, Kerri A. Dorsey, Edward P. Notari, Gregory A. Foster, David E. Krysztof, Fatemeh Musavi, Roger Y. Dodd, Susan L. Stramer, Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing Transfusion. ,vol. 50, pp. 1495- 1504 ,(2010) , 10.1111/J.1537-2995.2010.02622.X
Thomas R O'Brien, Interferon-alfa, interferon-|[lambda]| and hepatitis C Nature Genetics. ,vol. 41, pp. 1048- 1050 ,(2009) , 10.1038/NG.453
A. Probst, T. Dang, M. Bochud, M. Egger, F. Negro, P.-Y. Bochud, Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis. Journal of Viral Hepatitis. ,vol. 18, pp. 745- 759 ,(2011) , 10.1111/J.1365-2893.2011.01481.X
RJ Fontana, EA Hughes, M Bifano, H Appelman, D Dimitrova, R Hindes, WT Symonds, None, Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. American Journal of Transplantation. ,vol. 13, pp. 1601- 1605 ,(2013) , 10.1111/AJT.12209
Patricia C. Weber, Charles A. Lesburg, Michael B. Cable, Eric Ferrari, Zhi Hong, Anthony F. Mannarino, Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site Nature Structural & Molecular Biology. ,vol. 6, pp. 937- 943 ,(1999) , 10.1038/13305
S. Bressanelli, L. Tomei, A. Roussel, I. Incitti, R. L. Vitale, M. Mathieu, R. De Francesco, F. A. Rey, Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 96, pp. 13034- 13039 ,(1999) , 10.1073/PNAS.96.23.13034
Markus Reiser, Holger Hinrichsen, Yves Benhamou, Henk W. Reesink, Heiner Wedemeyer, Cristina Avendano, Neus Riba, Chan-Loi Yong, Gerhard Nehmiz, Gerhard G. Steinmann, Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C Hepatology. ,vol. 41, pp. 832- 835 ,(2005) , 10.1002/HEP.20612
Harvey J. Alter, Robert H. Purcell, James W. Shih, Jacqueline C. Melpolder, Michael Houghton, Qui-Lim Choo, George Kuo, Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis The New England Journal of Medicine. ,vol. 321, pp. 1494- 1500 ,(1989) , 10.1056/NEJM198911303212202
Adriaan J. van der Meer, Bart J. Veldt, Jordan J. Feld, Heiner Wedemeyer, Jean-François Dufour, Frank Lammert, Andres Duarte-Rojo, E. Jenny Heathcote, Michael P. Manns, Lorenz Kuske, Stefan Zeuzem, W. Peter Hofmann, Robert J. de Knegt, Bettina E. Hansen, Harry L. A. Janssen, Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. ,vol. 308, pp. 2584- 2593 ,(2012) , 10.1001/JAMA.2012.144878